Cargando…
Evaluation of the paclitaxel–ifosfamide–cisplatin (TIP) combination in relapsed and/or metastatic cervical cancer
BACKGROUND: Recurrent or metastatic cervical cancer represents an aggressive malignancy with a high rate of locoregional and distant failure. Therefore, we evaluated the three-drug combination of paclitaxel–ifosfamide–cisplatin (TIP). METHODS: Systemic chemotherapy-naive patients with advanced metas...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2768083/ https://www.ncbi.nlm.nih.gov/pubmed/19738606 http://dx.doi.org/10.1038/sj.bjc.6605305 |
_version_ | 1782173431668670464 |
---|---|
author | Kosmas, C Mylonakis, N Tsakonas, G Vorgias, G Karvounis, N Tsavaris, N Daladimos, T Kalinoglou, N Malamos, N Akrivos, T Karabelis, A |
author_facet | Kosmas, C Mylonakis, N Tsakonas, G Vorgias, G Karvounis, N Tsavaris, N Daladimos, T Kalinoglou, N Malamos, N Akrivos, T Karabelis, A |
author_sort | Kosmas, C |
collection | PubMed |
description | BACKGROUND: Recurrent or metastatic cervical cancer represents an aggressive malignancy with a high rate of locoregional and distant failure. Therefore, we evaluated the three-drug combination of paclitaxel–ifosfamide–cisplatin (TIP). METHODS: Systemic chemotherapy-naive patients with advanced metastatic/relapsed cervical cancer and a World Health Organization (WHO) performance status (PS) of 0–2 were eligible. TIP chemotherapy doses were paclitaxel 175 mg m(−2) on day 1, ifosfamide 2.5 g m(−2) on days 1+2, and cisplatin 40 mg m(−2) on days 1+2, with prophylactic granulocyte-colony stimulating factor. RESULTS: A total of 42 patients with recurrent/metastatic cervical cancer are evaluable for response and toxicity: median age: 56 (25–74) years; PS: 1 (0–2); histologies – squamous: 35, adenosquamous: 5, and adenocarcinoma: 2. Responses were overall response rate (RR): 62% (95% confidence interval (CI): 47.3–76.7%), with complete response (CR): 26% (95% CI: 12.7–39.3%), and partial response (PR): 36% (95% CI: 21.5–49.9%). Responses according to the relapse site were overall RR: 32% (95% CI: 13.7–50.3%) within previously irradiated pelvis vs 75% (95% CI: 57.7–92.3%) in extra-pelvic sites. Median time to progression (TTP) was 7 (range, 2–34+) months and median overall survival (OS) was 16.5 (range, 3–36+) months. Toxicities included grade 3–4 neutropenia: 83% (21% febrile neutropenia), grade 3–4 thrombocytopenia: 9%, no grade 3 neuropathy (35% grade 2), grade 2 asthenia/fatigue 15%, and no treatment-related deaths. CONCLUSION: TIP is an active regimen with acceptable toxicity in advanced/relapsed cervical cancer. |
format | Text |
id | pubmed-2768083 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2009 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-27680832010-10-06 Evaluation of the paclitaxel–ifosfamide–cisplatin (TIP) combination in relapsed and/or metastatic cervical cancer Kosmas, C Mylonakis, N Tsakonas, G Vorgias, G Karvounis, N Tsavaris, N Daladimos, T Kalinoglou, N Malamos, N Akrivos, T Karabelis, A Br J Cancer Clinical Study BACKGROUND: Recurrent or metastatic cervical cancer represents an aggressive malignancy with a high rate of locoregional and distant failure. Therefore, we evaluated the three-drug combination of paclitaxel–ifosfamide–cisplatin (TIP). METHODS: Systemic chemotherapy-naive patients with advanced metastatic/relapsed cervical cancer and a World Health Organization (WHO) performance status (PS) of 0–2 were eligible. TIP chemotherapy doses were paclitaxel 175 mg m(−2) on day 1, ifosfamide 2.5 g m(−2) on days 1+2, and cisplatin 40 mg m(−2) on days 1+2, with prophylactic granulocyte-colony stimulating factor. RESULTS: A total of 42 patients with recurrent/metastatic cervical cancer are evaluable for response and toxicity: median age: 56 (25–74) years; PS: 1 (0–2); histologies – squamous: 35, adenosquamous: 5, and adenocarcinoma: 2. Responses were overall response rate (RR): 62% (95% confidence interval (CI): 47.3–76.7%), with complete response (CR): 26% (95% CI: 12.7–39.3%), and partial response (PR): 36% (95% CI: 21.5–49.9%). Responses according to the relapse site were overall RR: 32% (95% CI: 13.7–50.3%) within previously irradiated pelvis vs 75% (95% CI: 57.7–92.3%) in extra-pelvic sites. Median time to progression (TTP) was 7 (range, 2–34+) months and median overall survival (OS) was 16.5 (range, 3–36+) months. Toxicities included grade 3–4 neutropenia: 83% (21% febrile neutropenia), grade 3–4 thrombocytopenia: 9%, no grade 3 neuropathy (35% grade 2), grade 2 asthenia/fatigue 15%, and no treatment-related deaths. CONCLUSION: TIP is an active regimen with acceptable toxicity in advanced/relapsed cervical cancer. Nature Publishing Group 2009-10-06 2009-09-08 /pmc/articles/PMC2768083/ /pubmed/19738606 http://dx.doi.org/10.1038/sj.bjc.6605305 Text en Copyright © 2009 Cancer Research UK https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Clinical Study Kosmas, C Mylonakis, N Tsakonas, G Vorgias, G Karvounis, N Tsavaris, N Daladimos, T Kalinoglou, N Malamos, N Akrivos, T Karabelis, A Evaluation of the paclitaxel–ifosfamide–cisplatin (TIP) combination in relapsed and/or metastatic cervical cancer |
title | Evaluation of the paclitaxel–ifosfamide–cisplatin (TIP) combination in relapsed and/or metastatic cervical cancer |
title_full | Evaluation of the paclitaxel–ifosfamide–cisplatin (TIP) combination in relapsed and/or metastatic cervical cancer |
title_fullStr | Evaluation of the paclitaxel–ifosfamide–cisplatin (TIP) combination in relapsed and/or metastatic cervical cancer |
title_full_unstemmed | Evaluation of the paclitaxel–ifosfamide–cisplatin (TIP) combination in relapsed and/or metastatic cervical cancer |
title_short | Evaluation of the paclitaxel–ifosfamide–cisplatin (TIP) combination in relapsed and/or metastatic cervical cancer |
title_sort | evaluation of the paclitaxel–ifosfamide–cisplatin (tip) combination in relapsed and/or metastatic cervical cancer |
topic | Clinical Study |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2768083/ https://www.ncbi.nlm.nih.gov/pubmed/19738606 http://dx.doi.org/10.1038/sj.bjc.6605305 |
work_keys_str_mv | AT kosmasc evaluationofthepaclitaxelifosfamidecisplatintipcombinationinrelapsedandormetastaticcervicalcancer AT mylonakisn evaluationofthepaclitaxelifosfamidecisplatintipcombinationinrelapsedandormetastaticcervicalcancer AT tsakonasg evaluationofthepaclitaxelifosfamidecisplatintipcombinationinrelapsedandormetastaticcervicalcancer AT vorgiasg evaluationofthepaclitaxelifosfamidecisplatintipcombinationinrelapsedandormetastaticcervicalcancer AT karvounisn evaluationofthepaclitaxelifosfamidecisplatintipcombinationinrelapsedandormetastaticcervicalcancer AT tsavarisn evaluationofthepaclitaxelifosfamidecisplatintipcombinationinrelapsedandormetastaticcervicalcancer AT daladimost evaluationofthepaclitaxelifosfamidecisplatintipcombinationinrelapsedandormetastaticcervicalcancer AT kalinogloun evaluationofthepaclitaxelifosfamidecisplatintipcombinationinrelapsedandormetastaticcervicalcancer AT malamosn evaluationofthepaclitaxelifosfamidecisplatintipcombinationinrelapsedandormetastaticcervicalcancer AT akrivost evaluationofthepaclitaxelifosfamidecisplatintipcombinationinrelapsedandormetastaticcervicalcancer AT karabelisa evaluationofthepaclitaxelifosfamidecisplatintipcombinationinrelapsedandormetastaticcervicalcancer |